CT & MRI company Medic Vision Imaging Solutions Ltd revealed on Tuesday that it has passed the US Food and Drug Administration (FDA) clearance for latest product, iQMR (intelligent Quick MR), to save cost, improve its productivity and boost patients experience and profitability.
The company said the new iterative image reconstruction technology enhances noisy MRI images and significantly increases SNR (signal to noise ratio). The new technology's capabilities enable the use of short MRI protocols and allow increased productivity, fewer repeating scans as well as better patient's experience.
Concurrently, the iQMR supports MRI scanners of all vendors and models, according to the company.
Following the US FDA's clearance, the company will now launch the iQMR at the upcoming ASNR 56th Annual Meeting. Additionally, Prof Lawrence N Tanenbaum, MD, FACR, VP and director of CT, MR & Advanced Imaging at RadNet, will present the results of a clinical study demonstrating the ability to reduce routine brain exam scan time by 30% without adversely affecting image quality using iQMR.
Genezen agrees manufacturing collaboration with Galibra Neuroscience
FDA grants Breakthrough Therapy Designation to Legacy Healthcare's CINAINU (LH-8)
FDA approves Vantis Vascular's 6F CrossFAST model
Blue Lake Biotechnology reports interim data from Phase 1/2a paediatric clinical trial of BLB201
Agilent to acquire Proscia for up to USD270m to expand digital pathology capabilities
Bristol Myers Squibb reports positive Phase 3 results for RYZ101 in neuroendocrine tumours
US WorldMeds awarded 2026 Vision of Hope Award
Urolution Medical secures FDA clearance for OpenFlo urinary catheter
Natera secures FDA Breakthrough Device designation for multi-cancer early detection assay
Medincell partner Teva secures FDA approval for monthly schizophrenia treatment
FDA approves Genentech's Tecentriq combination therapy for stage III colon cancer
Lupin Limited receives FDA approval for Phytonadione Injectable Emulsion USP
argenx reports positive Phase 2 results for FB102 in coeliac disease
Vir Biotechnology's VIR-5500 receives FDA Fast Track designation for prostate cancer